Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$11.55 -2.3%	$10.23	$3.85 ▼ $12.43	$1.75B	1.83	1.64 million shs	1.03 million shs
BPMC Blueprint Medicines	$129.36 +0.0%	$117.02	$73.04 ▼ $129.49	$8.35B	0.89	1.41 million shs	6.67 million shs
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	600 shs
HCM HUTCHMED	$16.23 +1.2%	$14.92	$11.51 ▼ $21.50	$2.83B	0.52	93,995 shs	20,308 shs
NEO NeoGenomics	$7.18 -1.1%	$7.51	$6.08 ▼ $19.12	$924.03M	1.63	1.30 million shs	1.12 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	-1.30%	+14.53%	+51.15%	+195.50%
BPMC Blueprint Medicines	0.00%	+0.80%	+1.05%	+56.67%	+9.78%
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
HCM HUTCHMED	0.00%	+0.92%	-5.09%	+7.72%	-17.32%
NEO NeoGenomics	0.00%	-4.66%	+2.69%	-25.31%	-50.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.871 of 5 stars	1.4	1.0	0.0	4.2	3.1	2.5	0.6
BPMC Blueprint Medicines	1.2287 of 5 stars	2.1	2.0	0.0	0.0	2.9	0.8	0.6
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	1.6253 of 5 stars	2.0	3.0	0.0	0.0	2.5	0.0	1.9
NEO NeoGenomics	3.6868 of 5 stars	4.2	3.0	0.0	0.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-8.47% Downside
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.86% Downside
DCPH Deciphera Pharmaceuticals	0.00	N/A	N/A	N/A
HCM HUTCHMED	2.00	Hold	$19.00	17.07% Upside
NEO NeoGenomics	2.45	Hold	$13.83	92.66% Upside

Current Analyst Ratings Breakdown

Latest NEO, BPMC, HCM, DCPH, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	9.80	N/A	N/A	$1.37 per share	8.43
BPMC Blueprint Medicines	$508.82M	16.42	N/A	N/A	$4.70 per share	27.52
DCPH Deciphera Pharmaceuticals	$174.91M	12.65	N/A	N/A	$4.38 per share	5.84
HCM HUTCHMED	$630.20M	4.49	$0.29 per share	55.84	$4.43 per share	3.66
NEO NeoGenomics	$672.36M	1.37	$0.43 per share	16.55	$7.03 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.02	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
DCPH Deciphera Pharmaceuticals	-$194.94M	-$2.21	N/A	N/A	N/A	-108.86%	-52.42%	-40.05%	N/A
HCM HUTCHMED	$37.73M	N/A	0.00	11.12	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)
NEO NeoGenomics	-$78.73M	-$0.61	N/A	79.78	N/A	-11.54%	-2.21%	-1.22%	7/29/2025 (Estimated)

Latest NEO, BPMC, HCM, DCPH, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	BPMC Blueprint Medicines	-$0.54	N/A	N/A	N/A	$171.34 million	N/A
7/29/2025	Q2 2025	NEO NeoGenomics	$0.0279	N/A	N/A	N/A	$182.91 million	N/A
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	NEO NeoGenomics	-$0.02	-$0.08	-$0.06	-$0.20	$171.38 million	$168.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
NEO NeoGenomics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
BPMC Blueprint Medicines	1.01	2.80	2.75
DCPH Deciphera Pharmaceuticals	N/A	4.19	3.94
HCM HUTCHMED	0.08	2.83	2.70
NEO NeoGenomics	0.38	2.05	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
BPMC Blueprint Medicines	N/A
DCPH Deciphera Pharmaceuticals	70.96%
HCM HUTCHMED	8.82%
NEO NeoGenomics	98.50%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
BPMC Blueprint Medicines	4.21%
DCPH Deciphera Pharmaceuticals	4.67%
HCM HUTCHMED	3.60%
NEO NeoGenomics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
DCPH Deciphera Pharmaceuticals	300	86.48 million	82.44 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
NEO NeoGenomics	2,200	128.70 million	125.61 million	Optionable

NEO, BPMC, HCM, DCPH, and ADPT Headlines

Recent News About These Companies

Emerald Advisers LLC Sells 701,749 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

July 13 at 6:08 AM | marketbeat.com

NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of "Hold" from Brokerages

July 13 at 4:25 AM | marketbeat.com

Emerald Mutual Fund Advisers Trust Sells 413,119 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

July 12 at 8:45 AM | marketbeat.com

Brown Advisory Inc. Lowers Stake in NeoGenomics, Inc. (NASDAQ:NEO)

July 10, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO

July 7, 2025 | prnewswire.com

NeoGenomics, Inc. (NEO) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

The past five years for NeoGenomics (NASDAQ:NEO) investors has not been profitable

July 5, 2025 | finance.yahoo.com

Here’s Why NeoGenomics (NEO) Sold Off in Q1

July 3, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO

July 2, 2025 | prnewswire.com

NeoGenomics Inc (NG9.SG) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

July 1, 2025 | businesswire.com

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

June 30, 2025 | businesswire.com

NeoGenomics Insider Trading Activity | NASDAQ:NEO | Benzinga

June 26, 2025 | benzinga.com

NeoGenomics Stock Price, Quotes and Forecasts - Benzinga

June 26, 2025 | benzinga.com

5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call

June 25, 2025 | msn.com

3 Hot Trades for Insiders, But Are They Good Buys for Investors? (NEO)

June 24, 2025 | insidertrades.com

NeoGenomics (NASDAQ:NEO) Sees Strong Trading Volume - What's Next?

June 24, 2025 | marketbeat.com

NeoGenomics Expands Board, Appoints New Director

June 24, 2025 | tipranks.com

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

June 24, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO

June 23, 2025 | globenewswire.com

Advisor Resource Council Makes New $872,000 Investment in NeoGenomics, Inc. (NASDAQ:NEO)

June 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Hot Trades for Insiders, But Are They Good Buys for Investors?
By Thomas Hughes | June 24, 2025
View 3 Hot Trades for Insiders, But Are They Good Buys for Investors?

NEO, BPMC, HCM, DCPH, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$11.55 -0.27 (-2.28%)

Closing price 04:00 PM Eastern

Extended Trading

$11.80 +0.25 (+2.21%)

As of 05:01 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Blueprint Medicines NASDAQ:BPMC

$129.36 +0.06 (+0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$129.34 -0.02 (-0.01%)

As of 04:59 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

HUTCHMED NASDAQ:HCM

$16.23 +0.19 (+1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$16.21 -0.02 (-0.12%)

As of 04:10 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

NeoGenomics NASDAQ:NEO

$7.18 -0.08 (-1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$7.33 +0.15 (+2.08%)

As of 04:13 PM Eastern

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time